Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.86 +0.69 (+0.77%)
Streaming Delayed Price Updated: 2:16 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
74 75 Next >
News headline image
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million ↗
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025. 
Via Benzinga
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of AstraZeneca to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Is AstraZeneca Stock a Buy? ↗
Via The Motley Fool
News headline image
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ASTRAZENECA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
News headline image
Why IonQ Is the Best Quantum Computing Stock to Buy Right Now ↗
Via The Motley Fool
News headline image
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts ↗
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review. 
Via Benzinga
News headline image
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption - Hagens Berman
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Law Enforcement
News headline image
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer ↗
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy 
Via Benzinga
News headline image
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN
From Rosen Law Firm
Via Business Wire
News headline image
Did AstraZeneca PLC Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - AZN
Via ACCESSWIRE
News headline image
AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment
Via ACCESSWIRE
News headline image
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Via ACCESSWIRE
News headline image
3 Unstoppable Stocks to Buy Right Now ↗
Via The Motley Fool
News headline image
Shareholders that lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about Securities Fraud Investigation - AZN
Via ACCESSWIRE
News headline image
AstraZeneca PLC INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by AstraZeneca PLC (AZN)
Via ACCESSWIRE
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains. 
Via Benzinga
News headline image
Levi & Korsinsky Investigates Possible Securities Fraud Violations by AstraZeneca PLC (AZN)
Via ACCESSWIRE
News headline image
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients ↗
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer. 
Via Benzinga
News headline image
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.